Intrahepatic CD69+Vδ1 T cells re-circulate in the blood of patients with metastatic colorectal cancer and limit tumor progression

Standard

Intrahepatic CD69+Vδ1 T cells re-circulate in the blood of patients with metastatic colorectal cancer and limit tumor progression. / Bruni, Elena; Cimino, Matteo Maria; Donadon, Matteo; Carriero, Roberta; Terzoli, Sara; Piazza, Rocco; Ravens, Sarina; Prinz, Immo; Cazzetta, Valentina; Marzano, Paolo; Kunderfranco, Paolo; Peano, Clelia; Soldani, Cristiana; Franceschini, Barbara; Colombo, Federico Simone; Garlanda, Cecilia; Mantovani, Alberto; Torzilli, Guido; Mikulak, Joanna; Mavilio, Domenico.

In: J IMMUNOTHER CANCER, Vol. 10, No. 7, e004579, 07.2022.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Bruni, E, Cimino, MM, Donadon, M, Carriero, R, Terzoli, S, Piazza, R, Ravens, S, Prinz, I, Cazzetta, V, Marzano, P, Kunderfranco, P, Peano, C, Soldani, C, Franceschini, B, Colombo, FS, Garlanda, C, Mantovani, A, Torzilli, G, Mikulak, J & Mavilio, D 2022, 'Intrahepatic CD69+Vδ1 T cells re-circulate in the blood of patients with metastatic colorectal cancer and limit tumor progression', J IMMUNOTHER CANCER, vol. 10, no. 7, e004579. https://doi.org/10.1136/jitc-2022-004579

APA

Bruni, E., Cimino, M. M., Donadon, M., Carriero, R., Terzoli, S., Piazza, R., Ravens, S., Prinz, I., Cazzetta, V., Marzano, P., Kunderfranco, P., Peano, C., Soldani, C., Franceschini, B., Colombo, F. S., Garlanda, C., Mantovani, A., Torzilli, G., Mikulak, J., & Mavilio, D. (2022). Intrahepatic CD69+Vδ1 T cells re-circulate in the blood of patients with metastatic colorectal cancer and limit tumor progression. J IMMUNOTHER CANCER, 10(7), [e004579]. https://doi.org/10.1136/jitc-2022-004579

Vancouver

Bibtex

@article{32c10005d870492e98324ddce9547149,
title = "Intrahepatic CD69+Vδ1 T cells re-circulate in the blood of patients with metastatic colorectal cancer and limit tumor progression",
abstract = "BACKGROUND: More than 50% of all patients with colorectal cancer (CRC) develop liver metastases (CLM), a clinical condition characterized by poor prognosis and lack of reliable prognostic markers. Vδ1 cells are a subset of tissue-resident gamma delta (γδ) T lymphocytes endowed with a broad array of antitumor functions and showing a natural high tropism for the liver. However, little is known about their impact in the clinical outcomes of CLM.METHODS: We isolated human γδ T cells from peripheral blood (PB) and peritumoral (PT) tissue of 93 patients undergone surgical procedures to remove CLM. The phenotype of freshly purified γδ T cells was assessed by multiparametric flow cytometry, the transcriptional profiles by single cell RNA-sequencing, the functional annotations by Gene Ontology enrichment analyses and the clonotype by γδ T cell receptor (TCR)-sequencing.RESULTS: The microenvironment of CLM is characterized by a heterogeneous immune infiltrate comprising different subsets of γδ tumor-infiltrating lymphocytes (TILs) able to egress the liver and re-circulate in PB. Vδ1 T cells represent the largest population of γδ TILs within the PT compartment of CLM that is greatly enriched in Vδ1 T effector (TEF) cells expressing constitutive high levels of CD69. These Vδ1 CD69+ TILs express a distinct phenotype and transcriptional signature, show high antitumor potential and correlate with better patient clinical outcomes in terms of lower numbers of liver metastatic lesions and longer overall survival (OS). Moreover, intrahepatic CD69+ Vδ1 TILs can egress CLM tissue to re-circulate in PB, where they retain a phenotype, transcriptional signature and TCR clonal repertoires resembling their liver origin. Importantly, even the increased frequencies of the CD69+ terminally differentiated (TEMRA) Vδ1 cells in PB of patients with CLM significantly correlate with longer OS. The positive prognostic score of high frequencies of CD69+ TEMRA Vδ1 cells in PB is independent from the neoadjuvant chemotherapy and immunotherapy regimens administered to patients with CLM prior surgery.CONCLUSIONS: The enrichment of tissue-resident CD69+ Vδ1 TEMRA cells re-circulating at high frequencies in PB of patients with CLM limits tumor progression and represents a new important clinical tool to either predict the natural history of CLM or develop alternative therapeutic protocols of cellular therapies.",
keywords = "Colorectal Neoplasms/immunology, Humans, Immunotherapy, Lymphocytes, Tumor-Infiltrating, Receptors, Antigen, T-Cell, gamma-delta, T-Lymphocyte Subsets/cytology, Tumor Microenvironment",
author = "Elena Bruni and Cimino, {Matteo Maria} and Matteo Donadon and Roberta Carriero and Sara Terzoli and Rocco Piazza and Sarina Ravens and Immo Prinz and Valentina Cazzetta and Paolo Marzano and Paolo Kunderfranco and Clelia Peano and Cristiana Soldani and Barbara Franceschini and Colombo, {Federico Simone} and Cecilia Garlanda and Alberto Mantovani and Guido Torzilli and Joanna Mikulak and Domenico Mavilio",
note = "{\textcopyright} Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.",
year = "2022",
month = jul,
doi = "10.1136/jitc-2022-004579",
language = "English",
volume = "10",
journal = "J IMMUNOTHER CANCER",
issn = "2051-1426",
publisher = "BioMed Central Ltd.",
number = "7",

}

RIS

TY - JOUR

T1 - Intrahepatic CD69+Vδ1 T cells re-circulate in the blood of patients with metastatic colorectal cancer and limit tumor progression

AU - Bruni, Elena

AU - Cimino, Matteo Maria

AU - Donadon, Matteo

AU - Carriero, Roberta

AU - Terzoli, Sara

AU - Piazza, Rocco

AU - Ravens, Sarina

AU - Prinz, Immo

AU - Cazzetta, Valentina

AU - Marzano, Paolo

AU - Kunderfranco, Paolo

AU - Peano, Clelia

AU - Soldani, Cristiana

AU - Franceschini, Barbara

AU - Colombo, Federico Simone

AU - Garlanda, Cecilia

AU - Mantovani, Alberto

AU - Torzilli, Guido

AU - Mikulak, Joanna

AU - Mavilio, Domenico

N1 - © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

PY - 2022/7

Y1 - 2022/7

N2 - BACKGROUND: More than 50% of all patients with colorectal cancer (CRC) develop liver metastases (CLM), a clinical condition characterized by poor prognosis and lack of reliable prognostic markers. Vδ1 cells are a subset of tissue-resident gamma delta (γδ) T lymphocytes endowed with a broad array of antitumor functions and showing a natural high tropism for the liver. However, little is known about their impact in the clinical outcomes of CLM.METHODS: We isolated human γδ T cells from peripheral blood (PB) and peritumoral (PT) tissue of 93 patients undergone surgical procedures to remove CLM. The phenotype of freshly purified γδ T cells was assessed by multiparametric flow cytometry, the transcriptional profiles by single cell RNA-sequencing, the functional annotations by Gene Ontology enrichment analyses and the clonotype by γδ T cell receptor (TCR)-sequencing.RESULTS: The microenvironment of CLM is characterized by a heterogeneous immune infiltrate comprising different subsets of γδ tumor-infiltrating lymphocytes (TILs) able to egress the liver and re-circulate in PB. Vδ1 T cells represent the largest population of γδ TILs within the PT compartment of CLM that is greatly enriched in Vδ1 T effector (TEF) cells expressing constitutive high levels of CD69. These Vδ1 CD69+ TILs express a distinct phenotype and transcriptional signature, show high antitumor potential and correlate with better patient clinical outcomes in terms of lower numbers of liver metastatic lesions and longer overall survival (OS). Moreover, intrahepatic CD69+ Vδ1 TILs can egress CLM tissue to re-circulate in PB, where they retain a phenotype, transcriptional signature and TCR clonal repertoires resembling their liver origin. Importantly, even the increased frequencies of the CD69+ terminally differentiated (TEMRA) Vδ1 cells in PB of patients with CLM significantly correlate with longer OS. The positive prognostic score of high frequencies of CD69+ TEMRA Vδ1 cells in PB is independent from the neoadjuvant chemotherapy and immunotherapy regimens administered to patients with CLM prior surgery.CONCLUSIONS: The enrichment of tissue-resident CD69+ Vδ1 TEMRA cells re-circulating at high frequencies in PB of patients with CLM limits tumor progression and represents a new important clinical tool to either predict the natural history of CLM or develop alternative therapeutic protocols of cellular therapies.

AB - BACKGROUND: More than 50% of all patients with colorectal cancer (CRC) develop liver metastases (CLM), a clinical condition characterized by poor prognosis and lack of reliable prognostic markers. Vδ1 cells are a subset of tissue-resident gamma delta (γδ) T lymphocytes endowed with a broad array of antitumor functions and showing a natural high tropism for the liver. However, little is known about their impact in the clinical outcomes of CLM.METHODS: We isolated human γδ T cells from peripheral blood (PB) and peritumoral (PT) tissue of 93 patients undergone surgical procedures to remove CLM. The phenotype of freshly purified γδ T cells was assessed by multiparametric flow cytometry, the transcriptional profiles by single cell RNA-sequencing, the functional annotations by Gene Ontology enrichment analyses and the clonotype by γδ T cell receptor (TCR)-sequencing.RESULTS: The microenvironment of CLM is characterized by a heterogeneous immune infiltrate comprising different subsets of γδ tumor-infiltrating lymphocytes (TILs) able to egress the liver and re-circulate in PB. Vδ1 T cells represent the largest population of γδ TILs within the PT compartment of CLM that is greatly enriched in Vδ1 T effector (TEF) cells expressing constitutive high levels of CD69. These Vδ1 CD69+ TILs express a distinct phenotype and transcriptional signature, show high antitumor potential and correlate with better patient clinical outcomes in terms of lower numbers of liver metastatic lesions and longer overall survival (OS). Moreover, intrahepatic CD69+ Vδ1 TILs can egress CLM tissue to re-circulate in PB, where they retain a phenotype, transcriptional signature and TCR clonal repertoires resembling their liver origin. Importantly, even the increased frequencies of the CD69+ terminally differentiated (TEMRA) Vδ1 cells in PB of patients with CLM significantly correlate with longer OS. The positive prognostic score of high frequencies of CD69+ TEMRA Vδ1 cells in PB is independent from the neoadjuvant chemotherapy and immunotherapy regimens administered to patients with CLM prior surgery.CONCLUSIONS: The enrichment of tissue-resident CD69+ Vδ1 TEMRA cells re-circulating at high frequencies in PB of patients with CLM limits tumor progression and represents a new important clinical tool to either predict the natural history of CLM or develop alternative therapeutic protocols of cellular therapies.

KW - Colorectal Neoplasms/immunology

KW - Humans

KW - Immunotherapy

KW - Lymphocytes, Tumor-Infiltrating

KW - Receptors, Antigen, T-Cell, gamma-delta

KW - T-Lymphocyte Subsets/cytology

KW - Tumor Microenvironment

U2 - 10.1136/jitc-2022-004579

DO - 10.1136/jitc-2022-004579

M3 - SCORING: Journal article

C2 - 35863820

VL - 10

JO - J IMMUNOTHER CANCER

JF - J IMMUNOTHER CANCER

SN - 2051-1426

IS - 7

M1 - e004579

ER -